NCT07784296Recruiting
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3500 (estimated)
- First submitted
- 28 Jul 2026
- Start date
- 19 Mar 2026
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Diseases
- High blood pressure
- NCT number
- NCT07784296
What you commit to
- Study type: Observational
- Planned participants: 3500
- From 19 Mar 2026 to the primary completion date, 31 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab.
- Pregnant women, women who may be pregnant, and nursing mothers
- Individuals currently participating in an interventional study
- Individuals deemed unsuitable for participation in this study by the researcher for other reasons
Who the study is looking for
- Korean patients aged 19 years or older diagnosed with hypertension
- Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
- Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
- Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yongin Severance Hospital Coordinator of this site? Confirm its status | Gyeonggi-do | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.